Research shows efficacy of dual GIP, GLP-1 RA in diabetes

A study in The Lancet showed that 15% to 82% of type 2 diabetes patients treated with LY3298176, a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, achieved the A1C target of at least 6.5% at 26 weeks, compared with 39% of those on dulaglutide or 2% on placebo. Researchers conducted a double-blind randomized Phase II study involving 316 patients with diabetes, ages 18 to 75, and found the LY3298176 group also had greater changes in mean body weight and waist circumference than the control group.

Endocrinology Advisor (10/29)